NASH
Clinical trials for NASH explained in plain language.
Never miss a new study
Get alerted when new NASH trials appear
Sign up with your email to follow new studies for NASH, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo pill aims to halt liver scarring in NASH patients
Disease control CompletedThis completed Phase 2 study tested whether a combination of two experimental drugs, K-877-ER and CSG452, can improve liver health in adults with nonalcoholic steatohepatitis (NASH) and liver fibrosis. The 228 participants received either the combination or a placebo. The main go…
Matched conditions: NASH
Phase: PHASE2 • Sponsor: Kowa Research Institute, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Natural supplement shows promise for fatty liver
Disease control CompletedThis study tested whether taking phytosterols (plant-based supplements) for 3 months can improve liver health, cholesterol, and insulin levels in people with nonalcoholic fatty liver disease (NAFLD). 27 participants took either phytosterol pills or a placebo. Researchers measured…
Matched conditions: NASH
Phase: NA • Sponsor: University of Jordan • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug DD01 shows promise for fatty liver in early trial
Disease control CompletedThis Phase 2 trial tested a drug called DD01 in 67 overweight or obese adults with a type of fatty liver disease (MASLD/MASH). The goal was to see if DD01 could safely reduce liver fat by at least 30% over 48 weeks compared to a placebo. The study is completed, and results will s…
Matched conditions: NASH
Phase: PHASE2 • Sponsor: Neuraly, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug shows promise for fatty liver – but early days
Disease control CompletedThis phase 2 trial tested elobixibat, a drug that blocks bile acid absorption in the gut, in 47 adults with nonalcoholic fatty liver disease (NAFLD) or its more severe form NASH. Participants received either elobixibat or a placebo for 16 weeks. The main goal was to see if the dr…
Matched conditions: NASH
Phase: PHASE2 • Sponsor: Albireo • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Blood tests may spot hidden liver damage in diabetics
Diagnosis CompletedThis study looked at whether two blood tests, eLIFT and FibroMeter, can accurately detect liver fibrosis (scarring) in people with type 2 diabetes. The researchers compared these blood tests to standard methods like FibroScan and liver biopsy. The goal is to find a simpler, less …
Matched conditions: NASH
Phase: NA • Sponsor: Nantes University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC
-
Liver disease Patients' vaccine response under the microscope
Knowledge-focused CompletedThis study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…
Matched conditions: NASH
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Can a phone app help fight fatty liver disease?
Knowledge-focused CompletedThis study tested whether a mobile health app called EL-FIT could help people with nonalcoholic steatohepatitis (NASH) exercise safely at home. Seventeen adults with NASH used the app and a Fitbit to do daily exercise as they wished. The main goal was to see if it was feasible an…
Matched conditions: NASH
Phase: NA • Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC